Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Vildagliptin Versus Dapagliflozin as Add on Therapy to Metformin on Cardiovascular Risk Factors in Egyptian Type II Diabetic Obese Patients: Potential Impact of Genetic Polymorphism

NCT07077525 is registered in ClinicalTrials.gov with Al-Azhar University as lead sponsor.

NCT NCT07077525
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07077525 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Vildagliptin Versus Dapagliflozin as Add on Therapy to Metformin on Cardiovascular Risk Factors in Egyptian Type II Diabetic Obese Patients: Potential Impact of Genetic Polymorphism
Lead sponsor
Al-Azhar University
Phase
Phase 4
Overall status
Completed
Start date
June 1, 2023
Completion date
August 31, 2024
Enrollment
196 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes